HER2 cancer vaccine - BioLife Science

Drug Profile

HER2 cancer vaccine - BioLife Science

Alternative Names: Her VAXX; HER-Vaxx; IMU 131; PEV 6A; PEV6

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator BioLife Science; Pevion Biotech
  • Developer Imugene; Pevion Biotech
  • Class
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gastric cancer
  • No development reported Breast cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer in Austria (IM, Injection)
  • 16 Jun 2016 Imugene Limited plans a phase Ib/II trial for Gastric cancer and Oesophageal cancer (Late stage disease, Metastatic disease) in Hong Kong, Taiwan and Thailand (NCT02795988)
  • 21 Apr 2015 Imugene files for patent protection for new HER2 cancer vaccine formulations in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top